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Background-—Clinical studies implicate trimethylamine N-oxide (TMAO; a gut microbiota-dependent nutrient metabolite) in
cardiovascular disease risk. There is a lack of population-based data on the role of TMAO in advancing early atherosclerotic
disease. We tested the prospective associations between TMAO and coronary artery calcium (CAC) and carotid intima-media
thickness (cIMT).
Methods and Results-—Data were from the Coronary Artery Risk Development in Young Adults Study (CARDIA), a biracial cohort of
US adults recruited in 1985–1986 (n=5115). We randomly sampled 817 participants (aged 33–55 years) who attended
examinations in 2000–2001, 2005–2006, and 2010–2011, at which CAC was measured by computed tomography and cIMT
(2005–2006) by ultrasound. TMAO was quantified using liquid chromotography mass spectrometry on plasma collected in 2000–
2001. Outcomes were incident CAC, defined as Agatston units=0 in 2000–2001 and >0 over 10-year follow-up, CAC progression
(any increase over 10-year follow-up), and continuous cIMT. Over the study period, 25% (n=184) of those free of CAC in 2000–
2001 (n=746) developed detectable CAC. In 2000–2001, median (interquartile range) TMAO was 2.6 (1.8–4.2) lmol/L. In
multivariable-adjusted models, TMAO was not associated with 10-year CAC incidence (rate ratio=1.03; 95% CI: 0.71–1.52) or CAC
progression (0.97; 0.68–1.38) in Poisson regression, or cIMT (beta coefficient: 0.009; 0.03 to 0.01) in linear regression,
comparing the fourth to the first quartiles of TMAO.
Conclusions-—In this population-based study, TMAO was not associated with measures of atherosclerosis: CAC incidence, CAC
progression, or cIMT. These data indicate that TMAO may not contribute significantly to advancing early atherosclerotic disease
risk among healthy early-middle-aged adults. ( J Am Heart Assoc. 2016;5:e003970 doi: 10.1161/JAHA.116.003970)
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R ecent studies implicate trimethylamine N-oxide (TMAO;a gut microbiota-dependent nutrient metabolite) in
advancing cardiovascular disease (CVD) risk.1–3 In the
apoE/ mouse, direct TMAO administration resulted in
increased foam cell formation, decreased reverse cholesterol
transport, and progression of aortic plaque lesions.1,3 In a
large sample of patients undergoing elective coronary
angiography, plasma TMAO concentrations were positively
associated with the rate of major CVD events over a 3-year
follow-up.2 Production of TMAO from dietary precursors relies,
in part, on gut bacteria, and atherosclerosis susceptibility has
been transferred through gut microbial transplantation in a
mouse model.4 These findings have generated interest given
that they may point to an important new prognostic variable
that is potentially modifiable through targeted diet or gut
microbial interventions.
Although animal models indicate that TMAO influences
CVD risk through atherosclerosis, there have been no
prospective studies of early atherosclerosis progression in
population-based samples. Previous human studies of TMAO
and atherosclerosis have been small or cross-sectional and
have yielded mixed results.5,6 Studies of TMAO and CVD
events have been conducted in older clinic-based samples
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with a high prevalence of comorbidities,1,6 and the relation-
ship between TMAO and atherosclerotic disease in younger
and healthier individuals is not known. Furthermore, previous
data indicate that significantly increased CVD risk may be
restricted to higher concentrations of TMAO.2 TMAO has been
shown to increase with age,2 and there is a need to
understand the relevance of lower TMAO concentrations that
are typical among younger individuals.
We tested the hypothesis that plasma TMAO is positively
associated with CAC incidence and progression using data from
CARDIA (Coronary Artery Risk Development in Young Adults), a
prospective, population-based cohort study of CVD risk evolu-
tion in adulthood. Coronary artery calcium (CAC) is ameasure of
atherosclerosis in the coronary arteries7 and is predictive of
fatal and nonfatal coronary heart disease and CVD events.8 In a
study of 4 racial/ethnic groups, participants with a CAC score
between 1 and 100 had a hazard rate of major coronary events
of 3.89, and those with a score between 101 and 300 had a
hazard rate of 7.08, as compared to individuals with a CAC
score of 0.8 CAC accelerates in early-middle adulthood,9 before
many comorbidities become prevalent in the general popula-
tion. We measured TMAO and quantified prospective associa-
tions between TMAOand10-year (1) CAC incidence and (2) CAC
progression. Our analysis tests the role of TMAO in the
advancement of atherosclerosis in a population-based sample
of adults at a critical life period for CVD prevention.
Materials and Methods
Study Sample
CARDIA, a longitudinal study of cardiometabolic disease risk
over adulthood, began in 1985–1986 with 5115 black and
white adults aged 18 to 30 years recruited from 4 metropoli-
tan areas (Birmingham, AL; Chicago, IL; Minneapolis, MN; and
Oakland, CA).10 There have been 7 follow-up examinations
(years 2, 5, 7, 10, 15, 20, and 25) with the majority of
survivors participating (91%, 86%, 81%, 79%, 74%, 72%, and
72%, respectively). CARDIA was approved by institutional
review boards of each field center; each study participant
provided informed written consent.
The 10-year study period for the present analysis was
2000–2001 through 2010–2011, years 15, 20, and 25 of
CARDIA. We randomly selected 860 individuals from within
race-sex strata of participants who attended the 2000–2001
exam; had CAC data from 2000 to 2001, 2005 to 2006, and
2010 to 2011; and complete covariate data from 2000 to
2001 (Figure). Of these participants, 817 had stored plasma
for analysis (Figure). The analytic sample comprised 211 black
men, 194 black women, 213 white men, and 199 white
women, representing 30%, 19%, 23%, and 19% of the
respective stratum-specific 2000–2001 exam totals.
TMAO Measurement
Participants were asked to fast ≥12 hours and avoid heavy
physical activity and smoking for the 2 hours before the
exam. Blood was drawn by venipuncture and stored at 4°C.
Within 90 minutes of collection, blood samples were sepa-
rated through centrifugation, aliquoted into airtight vials,
flash-frozen, and stored at 70°C.
TMAO was quantified using liquid chromatography/stable-
isotope dilution/multiple-reaction monitoring/mass spectrom-
etry by the University of North Carolina Nutrition Obesity
Research Center.11,12 Using 3 volume units of internal
standard-spiked acetonitrile (40 lmol/L of TMAO-d9, DLM-
n=5,115 CARDIA participants at baseline
2,878 participants attended follow-up exams at Years 15, 20, and 25
n=1,922 had complete CAC (Years 15, 20, 25) and covariate (Year 15) data
1 participant removed themselves from the study, n=5,114
n=1,157 black men n=1,480 black women n=1,170 white men n=1,307 white women
n=1,157 black men n=1,480 black women n=1,170 white men n=1,307 white women
n=339 black men n=481 black women n=563 white men n=439 white women
n=211 black men n=194 black women n=213 white men n=199 white women
Random selection of 215 from each race-sex stratum;
n=817 had available plasma for analysis
Figure. Flow diagram for eligibility and selection of study sample. CAC indicates coronary
artery calcium; CARDIA, Coronary Artery Risk Development in Young Adults Study.
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4779-1; Cambridge Isotope Laboratories, Inc., Tewksbury, MA),
samples were extracted for TMAO. Samples were chro-
matographed on an Atlantis HILIC Silica 3-lm 4.6950 mm
column (Waters Corporation, Milford, MA) in junction with a
Waters ACQUITY UPLC system. The 5-minute sequencing time
consisted of a gradient of 5% A for 0.05 minutes, to 15% A at
0.40 minutes, to 20% A at 1.00 minutes, to 30% A at 2.00 min-
utes, to 45% A at 2.55 minutes, to 55% A at 2.60 minutes, at
55% A for 0.90 minutes, to 5%A at 3.55 minutes, at 5% A for the
remainder of the sequence. Mobile phase A was composed of
10% acetonitrile and 90% water with 10 mmol/L of ammonium
formate and 0.125% formic acid; mobile phase B was 90%
acetonitrile and 10% water with 10 mmol/L of ammonium
formate and 0.125% formic acid. Flow rate was kept constant at
1 mL/min, and the column manager was set at 40°C for the
duration of the sequence. A Waters TQ detector equipped
with an electrospray ionization probe operating in positive-ion
mode was used for mass spectrometric analysis. TMAO
specificity was maintained by monitoring ion transitions from
precursor to product ions for both TMAO (75?58) and the
internal standard, TMAO-d9 (85?66). Quantification was
achieved by using a calibration curve constructed from the
peak area ratios of TMAO to its internal standard. Assay quality
assurance was monitored by routine analysis of pooled quality
control (QC) plasma at 2 concentrations of TMAO: a low quality
control (LQC) consisted of normal pooled human plasma with
endogenous TMAO and a high quality control (HQC) prepared by
spiking a stock solution of TMAO into pooled LQC plasma
sample for a final concentration of 50.0 lmol/L. Two of each
QC sample were extracted simultaneously with CARDIA sam-
ples and standards per each assay. Coefficients of variation
were 6.1% for TMAO, 5.8% for LQC, and 4.11% for HQC. Limits of
detection and quantification for TMAO were 0.03 and
0.06 lmol/L, respectively; the linear range was 0.06 to
500 lmol/L.13
CAC Measurement
In 2000–2001 and 2005–2006, an electron-beam computed
tomography (CT) scanner (Imatron C-150; GE Imatron, San
Francisco, CA) was used at the Chicago and Oakland field
centers, and a multidetector CT scanner (GE Lightspeed;
General Electric, Fairfield, CT; Siemens VZ; Siemens AG,
Munich, Germany) was used at the Birmingham and Min-
neapolis centers to obtain contiguous 2.5- to 3.0-mm-thick
transverse images from the root of the aorta to the apex of the
heart in 2 sequential scans; in 2010–2011, multidetector CT
scanners were used at all field centers.14 Scan data were
transmitted electronically to an independent CT reading center,
where a trained technician examined each image and identified
potential foci of CAC. An expert investigator adjudicated all
discordant scan pairs. There was high interobserver (k=0.89)
and intraobserver (k=0.95) agreement for the presence of
CAC.14 A total calcium score (Agatston units)7 was calculated
by summing the scores of all lesions within and across arteries
(left anterior descending, left main, circumflex, and right
coronary). Means of the 2 scans were used in analysis.
Other Measurements
Standard questionnaires were used to obtain demographic
(age, sex, race, and education) and behavioral (physical
activity, cigarette smoking, and alcohol consumption) data.
The validated interview-administered CARDIA Physical Activity
History queried past-year engagement in 13 activities, from
which a total activity score was calculated.15 Participants
reported their medication use for hypertension, lipid lowering,
and diabetes mellitus. Diet was assessed with an interviewer-
administered, validated dietary history in 1985–1986, 1992–
1993, and 2005–2006.16
Standardized protocols were used by trained staff for all
clinic measures. Height and weight were measured to the
nearest 0.50 cm and 0.20 kg, respectively, for body mass
index (BMI; kg/m2). Resting systolic and diastolic blood
pressure values were calculated as the mean of the second
and third of 3 measurements taken with a random-zero
sphygmomanometer. Plasma concentrations of total choles-
terol, high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and triglycerides were deter-
mined using enzymatic procedures or estimated by the
Friedewald equation. Serum glucose was measured using
hexokinase coupled to glucose-6-phosphate dehydrogenase.
Insulin was measured with the use of a radioimmunoassay.
Diabetes mellitus was defined as having fasting glucose level
≥126 mg/dL (7 mmol/L), 2-hour oral glucose tolerance test
(OGTT) ≥200 mg/dL (11.1 mmol/L), glycated hemoglobin
(HbA1c) ≥6.5% (48 mmol/mol), or use of hypoglycemic med-
ications. Plasma C-reactive protein (CRP) was measured using
high-sensitivity, nephelometry-based methods, soluble intra-
cellular adhesion molecule 1 (sICAM-1) by enzyme-linked
immunosorbent assay, and F2-isoprostanes by gas chromatog-
raphy/mass spectrometry. Urine albumin was measured using
a nephelometric procedure with a specific antialbumin mono-
clonal antibody and creatinine using the Jaffe method. Carotid
intima-media thickness (cIMT) was assessed in 2005–2006
from high-resolution B-mode ultrasound images at 3 levels:
common carotid artery, carotid artery bulb, and internal carotid
artery. We used the average maximum common cIMT (4
measurements) in analysis.
Statistical Analysis
Educational status was modeled as the maximum (at any visit)
reported years completed. Smoking was classified as current
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versus former/never. To account for typical dietary consump-
tion, we averaged consumption of TMAO precursor
food groups, including eggs and red meat, from years
7 (1992–1993) and 20 (2005–2006) of CARDIA, as well as
a measure of diet quality.17
We natural log-transformed CRP and triglycerides to
normalize data. Estimated glomerular filtration rate (eGFR)
(mL/min per 1.73 m2) was calculated from serum creatinine
using the 2009 CKD-EPI (CKD Epidemiology Collaboration)
equation.18 Urine albumin-creatinine ratios (UACRs) were
standardized to sex and race and expressed in milligrams per
gram of creatinine. We estimated insulin resistance
using homeostasis model assessment for insulin resistance
(HOMA-IR).19
Multivariable-adjusted regression models controlled for
2000–2001 covariate values. Variables were included in the
model as continuous, unless noted. A minimally adjusted
model (model 1) controlled for participant sex (male, female),
study center (Birmingham, Chicago, Minneapolis, or Oakland),
race (white, black), and age. Additional adjustment (model 2)
included years of education, current cigarette smoking
(current, never/former), intensity units of physical activity,
systolic blood pressure, LDL-C, HDL-C, natural log-trans-
formed triglycerides, HOMA-IR, BMI, natural log-transformed
high-sensitivity CRP, eGFR, and UACR. We tested the
sensitivity of models additionally adjusted for the use of
lipid-lowering or blood pressure mediation, sICAM-1 and F2-
isoprostanes, and dietary variables.
Incident CAC was defined as having an Agatston score of 0
in 2000–2001 (Year 15) and a score >0 at follow-up. We used
Poisson regression with an offset of time to incident CAC to
estimate the effect of TMAO on 10-year CAC incidence. To
account for CT error in detection of CAC, we reran models
based on a ≥10 score increase. We also defined 10-year CAC
progression as any CAC increase over follow-up (including
prevalent CAC in 2000–2001) and estimated relative rates of
10-year CAC progression with respect to TMAO using Poisson
regression.
We assessed the sensitivity of results to the specification
of TMAO in regression models. In addition to our primary
analysis of sample-based quartiles, we included linear and
quadratic specifications of continuous TMAO, and TMAO
categories with cutpoints from a previous study of TMAO and
CVD (<2.43, 2.43–3.66, 3.67–6.18, and >6.18 lmol/L).2
We additionally considered prospective associations
between TMAO and 10-year incidence of nonfatal CVD events
using Cox proportional hazards regression, association
between TMAO in 2000–2001 and level of common cIMT in
2005–2006 using linear regression, and the prospective
association between TMAO and 10-year changes in eGFR and
UACR using linear regression. We assessed potential selec-
tivity of our study sample by comparing those eligible for our
analysis (required to attend all 3 exams in the study period)
and all participants who attended the 2000–2001 exam.
Statistical analyses were completed with SAS (v9.4; SAS
Institute Inc., Cary, NC) and Stata/MP (v14.0; StataCorp LP,
College Station, TX) software.
Results
TMAO had an overall median (interquartile range; IQR) of
2.6 lmol/L (1.8–4.2), with medians of 1.3 lmol/L (IQR, 1.1,
1.5) in the lowest quartile and 6.6 lmol/L (5.1, 10.1) in the
highest quartile (Table 1). Quartile cutpoints of TMAO were
<1.8, 1.8 to 2.5, 2.6 to 4.2, and >4.2 lmol/L, respectively.
Across TMAO quartiles, there were significant differences in
age, education, sex, HDL-C, triglycerides, and eGFR (Table 1).
TMAO was positively associated with egg consumption
(P=0.02) and had a marginal positive association with red
meat consumption (P=0.07), but was not associated with
other dietary variables (Table 2).
CAC Incidence
Over the 10-year period, 184 individuals developed detectable
CAC among those who were free of CAC at baseline (n=746).
In multivariable-adjusted Poisson regression analysis, TMAO
measured in 2000–2001 was not significantly associated with
10-year CAC incidence, among the 746 individuals free of
CAC at baseline (rate ratio [RR]=1.03; 95% CI: 0.71–1.52, for
the fourth vs first quartile; Table 3). These findings were not
affected by adjustment for an extensive set of covariates,
including CVD risk factors, kidney function, or egg and red
meat consumption, or by alternative specifications of TMAO.
In addition, further adjustment for blood pressure or lipid-
lowering medication use did not materially change findings
(RR for CAC incidence=1.06; 95% CI: 0.72–1.55, comparing
the fourth to the first quartile of TMAO).
We were limited in our ability to reliably examine
associations according to higher levels of TMAO: 46% of
our sample had a TMAO value that fell within the first quartile
of TMAO concentration reported by Tang et al in an older
clinic-based sample.2 Effect estimates for incident CAC were
higher using the cutpoints of Tang et al, though did not
achieve statistical significance (RRs [95% CIs] for second,
third, and fourth category, respectively, compared to the first:
1.08 [0.75–1.54], 1.13 [0.77–1.67], and 1.09 [0.73–1.64];
Table 3). We tested other specifications of TMAO as well.
Linear TMAO from a continuous specification was not
statistically significantly associated with incident CAC
(RR=1.01; 95% CI: 0.99–1.02). A quadratic TMAO specifica-
tion also did not support an association between TMAO and
CAC (data not shown).
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Table 1. Participant Characteristics* According to Quartile of Plasma TMAO (n=817): CARDIA, 2000–2001
Quartiles of Plasma TMAO
P
Value†Q1 Q2 Q3 Q4
N 203 199 214 201
TMAO, lmol/L, median (IQR) 1.3 (1.1, 1.5) 2.1 (1.9, 2.3) 3.1 (2.8, 3.5) 6.6 (5.1, 10.1) <0.001
Age, y 39.8 (3.5) 39.7 (3.6) 40.8 (3.5) 40.3 (3.8) 0.002
Education, y 15.5 (2.4) 15.4 (2.4) 16.2 (2.6) 15.7 (2.5) 0.013
White race, % 44.8 48.2 55.1 52.7 0.141
Female, % 61.6 49.3 40.8 40.9 <0.001
Current smoking, % 14.8 21.6 21.6 21.7 0.240
Study center, %
Birmingham, Alabama (n=234) 27.8 24.4 23.9 23.9
Chicago, Illinois (n=248) 26.2 23.4 21.8 28.6
Minneapolis, Minnesota (n=165) 17.6 27.9 32.1 22.4
Oakland, California (n=170) 25.9 22.4 30.0 21.8 0.129
Physical activity units‡, median (IQR) 300 (138, 498) 286 (150, 476) 339 (174, 533) 295 (157, 472) 0.230
BMI, kg/m2 28.8 (6.8) 28.1 (5.2) 28.0 (5.2) 28.7 (5.7) 0.719
HOMA-IR§, median (IQR) 1.75 (1.26, 2.38) 1.75 (1.32, 2.53) 1.86 (1.31, 2.65) 1.91 (1.42, 2.71) 0.502
LDL cholesterol, mg/dL 115 (31) 117 (32) 112 (29) 118 (34) 0.267
HDL cholesterol, mg/dL 53 (14) 50 (13) 49 (14) 49 (15) 0.014
Triglycerides, mg/dL, natural log-transformed 4.4 (0.5) 4.5 (0.5) 4.5 (0.5) 4.5 (0.5) 0.017
Systolic blood pressure, mm Hg 112 (14) 111 (13) 113 (15) 112 (13) 0.714
CRP, lg/mL, natural log-transformed, median (IQR) 0.18 (0.18, 0.83) 0.16 (0.19, 0.62) 0.09 (0.14, 0.55) 0.18 (0.17, 0.66) 0.342
F2-isoprostanes, ng/L, median (IQR) 49.03 (40.9, 64.2) 49.4 (39.7, 66.7) 47.8 (37.9, 60.6) 53.2 (41.4, 71.0) 0.154
Soluble ICAM-1, lg/L 150 (37) 157 (41) 156 (67) 155 (41) 0.256
Estimated glomerular filtration rate (eGFR)||, mL/min per
1.73 m2
106 (16) 102 (16) 100 (17) 101 (17) 0.002
eGFR <60 mL/min per 1.73 m2, % 0 0 1.40 1.00 0.161
eGFR <100 mL/min per 1.73 m2, % 37.9 48.7 52.3 48.3 0.023
Urine albumin/creatinine ratio (UACR), mg/g, median (IQR) 3.88 (3.18, 5.94) 3.76 (2.84, 5.37) 3.85 (3.01, 6.3) 3.88 (3.12, 6.96) 0.554
UACR <30 mg/g, % 2.46 1.51 4.21 3.98 0.337
History of diabetes mellitus¶, % 3.45 4.02 5.14 2.49 0.553
Blood pressure medication use#, % 8.9 10.1 8.3 5.9 0.509
Lipid-lowering medication use**, % 0.49 3.02 3.21 0.99 0.097
ACE indicates angiotensin-converting enzyme; BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CRP, C-reactive protein; Hb1Ac, glycated hemoglobin; HDL, high-density lipoprotein; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; HOMA-IR, homeostasis model
assessment for insulin resistance; ICAM-1, intracellular adhesion molecule 1; IQR, interquartile range; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test; TMAO,
trimethylamine N-oxide.
*Mean (SD) unless noted.
†
Comparisons across TMAO quartiles were from chi-square test for categorical variables, the Kruskal–Wallis test for means, and the Brown–Mood test (multisample median test) for
medians.
‡
Physical activity units derived from the CARDIA physical activity questionnaire and reflect frequency and intensity of engagement in 13 activities.15
§
HOMA-IR defined according to Matthews et al.19
||
eGFR was calculated from serum creatinine using the 2009 CKD-EPI equation.18
¶
Any history of diabetes mellitus from 1985 to 1986 (CARDIA baseline), defined as having at least 1 of the following: fasting glucose ≥126 mg/dL, 2-hour OGTT ≥200 mg/dL, HbA1c
≥6.5%, or using hypoglycemic medications.
#
Blood pressure medications include: ACE inhibitors, alpha-adrenergic blockers, beta-adrenergic blockers, calcium-channel blockers, loop diuretics, potassium-sparing diuretics, thiazide
diuretic use.
**Lipid-lowering medication use include: HMG-CoA reductase inhibitors (statins), gemfibrozil.
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In multivariable-adjusted Poisson regression analysis, TMAO
was also not associated with CAC progression over the 10-
year follow-up period (RR=0.97; 95% CI: 0.68–1.38, for the
fourth vs first quartile; Table 4). Results did not change with
additional adjustment for lipid-lowering or blood pressure
medication use (RR for CAC progression=0.99; 95% CI: 0.70,
1.41, for the fourth vs first quartile). CAC progression was
also not statistically significantly associated with TMAO
using the cutpoints of Tang et al (Table 4) or with specifi-
cations of continuous TMAO as linear or quadratic (data not
shown).
Other CVD-Related Outcomes
TMAO was not associated with cIMT measured in 2005–2006
(beta coefficients [95% CI] from a linear regression model was
0.009 [0.03, 0.01], comparing the fourth to the first
quartiles of TMAO; Table 5). TMAO was not associated with
the 10-year incidence of nonfatal CVD events, although power
for this analysis was low, with only 22 CVD events in our
sample over the 10-year study period (data not shown). TMAO
was also not associated with 10-year changes in eGFR or
UACR (Table 6). In cross-sectional analysis (2000–2001),
there was a suggestion of higher TMAO at lower eGFR,
although few participants had low eGFR values (n=5 had eGFR
<60 mL/min per 1.73 m2) and differences were not statis-
tically significant (data not shown).
Individuals who were eligible for our study were somewhat
healthier, as compared to those who were ineligible, as
expected, given our requirements of survival and participation
in the 3 CARDIA exams over the 10-year study period.
However, CVD event rates were not appreciably different
among those eligible and ineligible for our study. Furthermore,
we note that a large percentage of participants had incident or
progressive CAC over follow-up; in addition, measures
predictive of CAC in previous work were significantly asso-
ciated in our sample, including sICAM-120 and duration of
adiposity21 (data not shown).
Discussion
In a cohort of adults, aged 33 to 45, plasma TMAO
concentration was not associated with CAC incidence or
progression over 10 years of follow-up, after accounting for
an extensive set of potential confounders. Nor was TMAO
associated with other measures of CVD risk, including cIMT,
insulin resistance, inflammatory markers, and lipids. TMAO
concentrations in our sample were notably lower than in
previous work that showed a positive association between
TMAO and CVD risk.2 Our results contribute to refining our
understanding of population subgroups that may be most
susceptible to the adverse effects of TMAO. In particular, our
findings suggest that TMAO levels may not significantly
influence progression of early atherosclerosis.
Our results are not consistent with our hypothesis that
TMAO is positively associated with CAC in an early-middle-age
sample; however, our results are not necessarily inconsistent
with previous reports that support a role for higher TMAO
concentrations in advancing CVD risk in other groups. In a
Table 2. Dietary Variables* (Mean [SD]) According to Quartiles of TMAO
Quartiles of Plasma TMAO
P ValueQ1 Q2 Q3 Q4
Fast food consumption, times/week† 2.11 (2.91) 2.18 (2.72) 1.87 (2.11) 2.30 (3.02) 0.477
Diet quality score‡ 62.9 (11.0) 62.2 (10.8) 63.2 (10.2) 62.5 (10.3) 0.693
Eggs 0.49 (0.46) 0.64 (0.79) 0.57 (0.47) 0.67 (0.79) 0.008
Processed meat 0.83 (0.81) 0.92 (0.88) 0.95 (0.96) 0.92 (0.91) 0.372
Lean red meat 0.44 (0.49) 0.47 (0.50) 0.51 (0.51) 0.52 (0.74) 0.396
Regular (nonlean) red meat 1.60 (1.44) 1.81 (1.62) 1.69 (1.29) 1.88 (1.37) 0.071
Poultry 1.46 (1.14) 1.57 (1.56) 1.45 (1.15) 1.47 (1.25) 0.985
Fish 0.04 (0.12) 0.03 (0.09) 0.05 (0.17) 0.04 (0.14) 0.952
Total red meat§ 2.87 (2.22) 3.21 (2.41) 3.14 (2.25) 3.32 (2.30) 0.120
Total precursorsk 3.42 (2.46) 3.9 (2.88) 3.76 (2.45) 4.04 (2.72) 0.056
CARDIA indicates Coronary Artery Risk Development in Young Adults Study; TMAO, trimethylamine N-oxide.
*Unless otherwise noted, mean consumption, in servings per day, of food groups reported on dietary assessments at CARDIA exams in 1992–1993 and 2005–2006.
†
Self-reported fast food consumption from 2000 to 2001.
‡
Mean diet quality scores from dietary assessments at CARDIA exams in 1992–1993 and 2005–2006. CARDIA diet quality score derived as previously described.17 Higher scores reflect
greater consumption of food groups hypothesized to be beneficial to health, relative to consumption of food groups considered adverse to health.
§
Total red meat is sum of servings per day of processed meat, lean red meat, and regular (nonlean) red meat.
k
Total precursors is the sum of servings per day of eggs, processed meat, lean red meat, regular (nonlean) red meat, poultry, and fish.
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cohort of 4007 patients undergoing elective coronary angiog-
raphy, Tang et al found that TMAO significantly predicted 3-
year major CVD events (n=513) among individuals at the
highest quartile of TMAO (>6.18 lmol/L), as compared to the
lowest quartile, in adjusted analysis (hazard rate [HR]=1.49;
95% CI, 1.10–2.03), but not at lower TMAO concentrations
(HR=1.08, 0.79–1.48 and 1.15, 0.85–1.56 for second and
third quartiles, respectively).2 Using the same TMAO cut-
points, we observed similar point estimates for the second
and third categories (respectively, 1.08 and 1.13; Table 3),
but we had limited power to estimate the effect of TMAO
among individuals (n=99; 33 CAC) with TMAO >6.18 lmol/L
(at which we observed an estimate of 1.09 [0.73–1.64]). It is
possible that the adverse effect of TMAO is limited to higher
concentrations than we observed in our sample.
It is also possible that TMAO may be etiologically relevant
at later stages of the disease process, within high-risk
subgroups, or among older individuals. We and others2 have
found that TMAO increases significantly with age. Strong
support for a role of TMAO in CVD risk came initially from a
sample of individuals receiving diagnostic angiography with a
mean age of 63 years.2 Study investigators controlled for an
extensive set of risk factors in regression analysis and showed
that TMAO was also predictive among lower-risk individuals in
a subgroup analysis.2 These analytic approaches will not,
however, compensate for meaningful differences between
studies, most notably the younger age distribution and lower
overall risk burden in our sample, if there are differential
subgroup effects. For example, some studies show that TMAO
may be most predictive of CVD among individuals with known
comorbidities, including diabetes mellitus,22 heart failure,23–25
or chronic kidney disease,26 though such results have been
inconsistently reported.27
High TMAO reflects higher consumption of TMAO precur-
sors, some of which are also hypothesized to influence CVD
risk. In the present analysis, statistical adjustment for dietary
precursors, including red meat, eggs, and fish, did not
materially impact effect estimates. The role of dietary
precursors for TMAO in CVD risk is mixed, with red meat
shown to increase CVD risk, whereas fish is considered
cardioprotective.28 In addition, recent data suggest that oral
supplementation with TMAO precursor L-carnitine may con-
tribute to lowering plasma lipoprotein(a).29
We assessed the role of TMAO in advancing early
atherosclerotic disease. One consideration is the relevance
of studying a relatively young and healthy sample. However,
this is a critical life period for primary prevention activities and
25% of our study sample developed detectable CAC over the
Table 3. Multivariable-Adjusted Effect Estimates (95% CI) for Plasma TMAO and 10-Year CAC Incidence*
Sample-Based Quartiles of Plasma TMAO, lmol/L
Q1 (Ref) Q2 Q3 Q4
TMAO, lmol/L <1.71 1.71 to 2.50 2.60 to 4.20 >4.20
n (cases) 190 (51) 186 (49) 192 (53) 178 (60)
Rate ratios (95% CIs) for TMAO and 10-year CAC incidence†
Model 1‡ 1 0.89 (0.60, 1.31) 0.83 (0.56, 1.23) 1.06 (0.73, 1.54)
Model 2§ 1 0.88 (0.59, 1.30) 0.82 (0.55, 1.23) 1.03 (0.71, 1.52)
Categories of TMAO (lmol/L) Presented in Tang et al2
C1 (Ref) C2 C3 C4
TMAO, lmol/L <2.43 2.43 to 3.66 3.67 to 6.18 >6.18
n (cases) 355 (90) 174 (52) 118 (38) 99 (33)
Rate ratios (95% CIs) for TMAO and 10-year CAC incidence
Model 1 1 1.05 (0.74, 1.49) 1.13 (0.77, 1.66) 1.12 (0.75, 1.68)
Model 2 1 1.08 (0.75, 1.54) 1.13 (0.77, 1.67) 1.09 (0.73, 1.64)
BMI indicates body mass index; CAC, coronary artery calcium; CARDIA, Coronary Artery Risk Development in Young Adults Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin
resistance; LDL-C, low-density lipoprotein cholesterol; TMAO, trimethylamine N-oxide; UACR, urine albumin/creatinine ratio.
*CAC incidence was defined as having CAC score=0 in 2000–2001 and CAC score >0 in 2005–2006 or 2010–2011. CAC cases are incident CAC over the 10-year study period.
†
Rate ratios (RR) were obtained from Poisson regression using SAS PROC GENMOD. TMAO was measured in 2000–2001 and CAC was assessed at 2000–2001, 2005–2006, and 2010–
2011.
‡
Model 1 was adjusted for age, race (black/white), sex (male/female), and CARDIA field center (Birmingham, AL; Chicago, IL; Minneapolis, MN; Oakland, CA).
§
Model 2 was additionally adjusted for physical activity (CARDIA physical activity units), smoking (never or former/current), BMI, CRP (natural log-transformed), HOMA-IR, eGFR, UACR,
LDL-C, HDL-C, systolic blood pressure, and triglycerides (natural log-transformed).
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10-year study period. In addition, many studies have docu-
mented strong associations between risk factors measured
from young adulthood to early middle age and CAC. For
example, in previous CARDIA analysis, CAC at ages 33 to 55
has been associated with obesity,21,30 F2-isoprostanes,
20 and
nonoptimal lipids31 measured in young adulthood or early
middle age. Other studies have reported associations
between traditional CVD risk factors and CAC measured at
even younger ages.32
We studied CAC because it is a strong predictor of future
CVD events among asymptomatic individuals8,33 and because
of compelling data that support an etiological role for TMAO in
atherosclerosis.1,3,4 In the apoE/ mouse model, TMAO
increased foam cell formation and accelerated progression of
aortic plaque lesions.1 Furthermore, in cross-sectional anal-
ysis of 1020 patients, there was a positive dose-response
relationship between plasma TMAO and the number of
coronary vessels (0–3) with ≥50% stenosis on diagnostic
Table 4. Multivariable-Adjusted Effect Estimates (95% CI) for TMAO and 10-Year CAC Progression*
Sample-Based Quartiles of Plasma TMAO, lmol/L
Q1 (Ref) Q2 Q3 Q4
TMAO, lmol/L <1.71 1.71 to 2.50 2.60 to 4.20 >4.20
n (cases) 203 (58) 199 (54) 214 (65) 201 (74)
Rate ratios (95% CIs) for TMAO and 10-year CAC progression†
Model 1‡ 1 0.85 (0.59, 1.24) 0.81 (0.56, 1.16) 1.01 (0.71, 1.43)
Model 2§ 1 0.85 (0.58, 1.23) 0.79 (0.55, 1.15) 0.97 (0.68, 1.38)
Categories of TMAO (lmol/L) Presented in Tang et al2
C1 (Ref) C2 C3 C4
TMAO, lmol/L <2.43 2.43 to 3.66 3.67 to 6.18 >6.18
n (cases) 378 (100) 195 (66) 136 (66) 108 (38)
Rate ratios (95% CIs) for TMAO and 10-year CAC progression
Model 1 1 1.05 (0.77, 1.45) 1.06 (0.75, 1.51) 1.09 (0.75, 1.59)
Model 2 1 1.08 (0.78, 1.49) 1.02 (0.72, 1.46) 1.06 (0.72, 1.56)
BMI indicates body mass index; CAC, coronary artery calcium; CARDIA, Coronary Artery Risk Development in Young Adults Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin
resistance; LDL-C, low-density lipoprotein cholesterol; TMAO, trimethylamine N-oxide; UACR, urine albumin/creatinine ratio.
*CAC progression was defined as any increase in detectable CAC over the 10-year period, including incident CAC (CAC score=0 in 2000–2001 and CAC score >0 in 2005–2006 or 2010–
2011) among those with CAC=0 in 2000–2001 or any increase in CAC in 2005–2006 or 2010–2011 among those with CAC >0 in 2000–2001.
†
Rate ratios (RR) were obtained from Poisson regression using SAS PROC GENMOD. TMAO was measured in 2000–2001 and CAC was assessed at 2000–2001, 2005–2006, and 2010–
2011.
‡
Model 1 was adjusted for age, race (black/white), sex (male/female), and CARDIA field center (Birmingham, AL; Chicago, IL; Minneapolis, MN; Oakland, CA).
§
Model 2 was additionally adjusted for physical activity (CARDIA physical activity units), smoking (never or former/current), BMI, CRP (natural log-transformed), HOMA-IR, eGFR, UACR,
LDL-C, HDL-C, systolic blood pressure, and triglycerides (natural log-transformed).
Table 5. Multivariable-Adjusted* Effect Estimates (95% CI) for the Association Between TMAO (2000–2001) and Carotid Intima-
Media Thickness (2005–2006)
Quartiles of Plasma TMAO
Q1 Q2 Q3 Q4
cIMT†
n‡ 193 180 200 193
Mean (SD) cIMT 0.80 (0.12) 0.79 (0.11) 0.81 (0.15) 0.80 (0.13)
Beta coefficient (95% CI)§ Ref 0.014 (0.04, 0.01) 0.006 (0.03, 0.02) 0.009 (0.03, 0.01)
cIMT indicates carotid intima-media thickness; TMAO, trimethylamine N-oxide.
*Regression models adjusted for age, sex, race, study center, educational attainment, current smoking status, physical activity, and body mass index. All covariates measured in 2000–
2001.
†




Beta coefficient from multivariable-adjusted linear regression for the association between TMAO (2000–2001) and cIMT (2005–2006).
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coronary angiography.1 It is possible that our measures of
atherosclerosis—CAC and carotid IMT—do not reflect TMAO-
related atherosclerotic processes. The precise mechanism
through which TMAO may impact CVD risk remains under
study, with reported data supporting potential effects on
reverse cholesterol transport3 and platelet activation.34 More
work is needed to determine the underlying mechanisms by
which TMAO may affect disease risk, but published findings
underscore the range of possible pathways through which
TMAO may influence CVD risk. Still, our results were not
expected, given that individuals with higher CAC scores have
been shown to have greater total coronary plaque (calcified
and noncalcified),35 and calcification is associated with high-
risk plaques and with acute coronary syndrome lesions.36–38
A strength of our study was the ability to study the
prospective association between TMAO and CAC in a
relatively young and healthy population-based sample. We
know of no other prospective study of TMAO and atheroscle-
rosis in a population-based sample. Cross-sectional studies
have yielded inconsistent support for an association between
TMAO and atherosclerosis and have been limited by small
samples or patient-based selection.5,25,39–41
In addition, our study limited the potential for confounding
by comorbidities, such as kidney function, an independent risk
factor for CVD.42 TMAO is excreted in urine,43,44 and
circulating TMAO increases as kidney function declines.45
The consideration that circulating TMAO may reflect kidney
function, however, does not refute the possibility that high
TMAO concentrations may adversely affect cardiovascular
health, if, for example, TMAO influences atherosclerosis
through a pathway related to declining kidney function. In
C57BL/6J male mice, administration of TMAO promoted renal
fibrosis and dysfunction.26 Among 1434 Framingham Off-
spring Study participants, TMAO was 1 of 16 metabolites
identified to be positively associated with incident chronic
kidney disease (n=123 cases) over 8 years of follow-up.46 We
found some evidence that TMAO was associated with
decreased kidney function in our analysis, though findings
were not statistically significant.
Additional strengths of the CARDIA study include extensive
covariate data on traditional CVD risk factors, diet, kidney
function, and inflammatory markers. In addition, our study
captured a period of significant CAC progression—the
prevalence of individuals with any CAC increased from 9%
to 30% over the 10-year follow-up—and an important period
for CVD prevention activities.
Along with the relative youth of our sample, eligibility
criteria for our study selected for a generally healthy sample.
Specifically, our requirement that individuals have all 3 CAC
measurements eliminated participants who died or were lost
to follow-up over the 10-year study period. However, as noted,
CVD event rates were not appreciably different among those
eligible and ineligible for our study, and significant associa-
tions have been found in previous studies of incident CAC
with this same sample restriction.
Our study was not powered for the analysis of CVD events
or subgroup differences, though, importantly, we had suffi-
cient power to replicate previously reported associations
between risk factors and CAC progression in the full CARDIA
sample.20,21 Our analysis relied on analysis of TMAO from
plasma that had been stored at 70°C from the time of
fasting blood collection at the 2000–2001 exam. TMAO has
been shown to be stable when stored at 80°C over 5 years,
despite multiple freeze-thaw cycles,47 but we know of no data
on the stability of TMAO over 15 years. TMAO concentrations
(median=2.6 lmol/L [IQR, 1.8–4.2]) in our sample were
comparable to age-matched levels in a community-based
sample (n=349) of healthy individuals.47
In conclusion, in this population-based sample of early-
middle-aged adults, plasma TMAO was not associated with
Table 6. Multivariable-Adjusted* Effect Estimates (95% CI) for Prospective Associations Between TMAO (2000–2001) and 10-Year
Changes in Measures of Kidney Function
Quartiles of Plasma TMAO
Q1 Q2 Q3 Q4
10-year changes†
10-year change in eGFR 8.53 (14.3) 5.71 (13.9) 7.09 (14.0) 8.10 (13.5)
Beta-coefficients (95% CI) Ref 2.80 (0.07, 5.53) 1.05 (1.66, 3.77) 0.22 (2.53, 2.96)
10-year change in UACR 0.63 (14.8) 3.30 (13.5) 3.24 (26.8) 1.04 (19.7)
Beta-coefficients (95% CI) Ref 2.63 (1.25, 6.50) 2.34 (1.51, 6.19) 0.21 (3.68, 4.11)
eGFR indicates estimated glomerular filtration rate; TMAO, for trimethylamine N-oxide; UACR, urine albumin/creatinine ratio.
*Regression models adjusted for age, sex, race, study center, educational attainment, current smoking status, physical activity, and body mass index. All covariates measured in 2000–
2001.
†Beta coefficients from linear regression for the association between TMAO (2000–2001) and 10-year changes in eGFR or UACR. Change variables were defined as 10-year difference in
each continuous measure (eg, [2010–2011 eGFR][2000–2001 eGFR]).
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10-year CAC incidence or progression or cIMT. Our results
support the need for further research to define the role of
TMAO in CVD-related outcomes across the distribution of
circulating TMAO concentrations and among population
groups with variable underlying CVD risk or risk factors such
as diet or gut microbiota.
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